FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to lyophilized composition comprising epotilone in the effective amount and mannitol or cyclodextrin. The second variant of the lyophilized composition involves epotilone and hydroxypropyl-beta-cyclodextrin. The preferable content of epotilone in the lyophilized composition is from 0.1% to 1.5%, and cyclodextrin - from 90% to 99% as measured for the total mass of solid components. Epotilone-containing lyophilized compositions can be used fro preparing an anti-tumor medicinal agent useful for parenteral administration and the lyophilized composition can be reduced preferably before administration directly. Epotilone-containing lyophilized compositions show improved indices of epotilone solubility and can retain stability for 24-36 months at temperature from 2°C to 30°C being without change of the solubility index.
EFFECT: improved and valuable properties of composition.
10 cl, 4 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EPOTHILONE-CONTAINING COMPOSITIONS | 1999 |
|
RU2214246C2 |
| ANTICANCER PHARMACEUTICAL COMPOSITIONS AND METHOD OF TREATING BREAST CANCER | 2015 |
|
RU2581022C1 |
| ENZYMATIC METHOD FOR PREPARING EPOTILONES, CRYSTALLINE FORM OF EPOTILONE B AND ITS USING | 1999 |
|
RU2268306C2 |
| THERAPEUTIC COMPOSITIONS | 2004 |
|
RU2358729C2 |
| COMPOSITIONS WHICH CONTAIN EPOTHILONE, AND METHOD OF THEIR OBTAINING | 2005 |
|
RU2416407C2 |
| ANTITUMOUR ANTHRAFURANDIONE AND BASED PHARMACEUTICAL COMPOSITIONS | 2014 |
|
RU2554939C1 |
| ANTIFUNGAL SEMI-SYNTHETIC POLYENE ANTIBIOTIC, WATER-SOLUBLE SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS BASED THEREON | 2018 |
|
RU2688658C1 |
| PARENTERAL COMPOSITION FOR TREATMENT OF EPILEPSY | 1998 |
|
RU2242231C2 |
| APPLYING EPOTILONES FOR CANCER TREATMENT | 1999 |
|
RU2242229C2 |
| COMPOSITION FOR PARENTERAL ADMINISTRATION CONTAINING SIPONIMOD | 2018 |
|
RU2803937C2 |
